Colorectal carcinoma: A general overview and future perspectives in colorectal cancer

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Mármol, Inés ^a   Sánchez de Diego, Cristina ^a,b   Dieste, Alberto Pradilla ^a   Cerrada, Elena ^c   Yoldi, María Jesús Rodriguez ^a,d  

^a UNIVERSIDAD DE ZARAGOZA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

Agarose macrobeads; Anti inflammatories; Biomarkers; Colorectal carcinoma; Functional food; Gene expression profiling; Metal based drugs; Microbiota; ncRNA; Probiotics

Indexed keywords

APC PROTEIN; B RAF KINASE; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; K RAS PROTEIN; MICRORNA 101; MICRORNA 126; MICRORNA 143; MICRORNA 155; MICRORNA 20A; MICRORNA 21; MICRORNA 222; MICRORNA 29; MICRORNA 375; MICRORNA 9; MUTL PROTEIN HOMOLOG 1; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; UNTRANSLATED RNA; WNT PROTEIN;

CHROMOSOMAL INSTABILITY; COLORECTAL CARCINOMA; DEATH; DNA REPAIR; DYSBIOSIS; FAMILIAL COLON POLYPOSIS; FUSOBACTERIUM; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; MICROBIOME; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; CANCER STAGING; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM STAGING; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 85010764998     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010197     Document Type: Review

References (303)

1. Quek, X.C.; Thomson, D.W.; Maag, J.L.; Bartonicek, N.; Signal, B.; Clark, M.B.; Gloss, B.S.; Dinger, M.E. LncRNAdb v2. 0: Expanding the reference database for functional long noncoding RNAs. Nucleic Acids Res. 2014, 43, 168–173.
2. Amaral, P.P.; Clark, M.B.; Gascoigne, D.K.; Dinger, M.E.; Mattick, J.S. LncRNAdb: A reference database for long noncoding RNAs. Nucleic Acids Res. 2011, 39, 146–151.
3. Xie, B.; Ding, Q.; Han, H.; Wu, D. miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics 2013, 29, 638–644.
4. Xie, B.; Ding, Q.; Wu, D. Text mining on big and complex biomedical literature. Big Data Anal. Bioinform. Healthc. 2014.
5. Xie, B.; Hochberg, R.; Ding, Q.; Wu, D. miRSAT & miRCDB: An Integrated microRNA Sequesce Analysis Tool and a Cancer-Associated microRNA Database. In Proceedings of the ISCA 2nd International Conference on Bioinformatics and Computational Biology, BICoB-2010, Sheraton Waikiki Hotel, Honolulu, HI, USA, 24–26 March 2010; pp. 159–164.
6. Stewart, B.; Wild, C.P. (Eds.) World Cancer Report 2014; International Agency for Research on Cancer (IARC): Lyon, France, 2014.
7. Brody, H. Colorectal cancer. Nature 2015, 521, S1.
8. Cunningham, D.; Atkin, W.; Lenz, H.-J.; Lynch, H.T.; Minsky, B.; Nordlinger, B.; Starling, N. Colorectal cancer. Lancet 2010, 375, 1030–1047.
9. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759–767.
10. Lynch, H.T.; de la Chapelle, A. Hereditary colorectal cancer. N. Engl. J. Med. 2003, 348, 919–932.
11. Umar, A.; Boland, C.R.; Terdiman, J.P.; Syngal, S.; de la Chapelle, A.; Rüschoff, J.; Fishel, R.; Lindor, N.M.; Burgart, L.J.; Hamelin, R. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004, 96, 261–268.
12. Stoffel, E.M.; Kastrinos, F. Familial colorectal cancer, beyond lynch syndrome. Clin. Gastroenterol. Hepatol. 2014, 12, 1059–1068.
13. Levin, B.; Lieberman, D.A.; McFarland, B.; Smith, R.A.; Brooks, D.; Andrews, K.S.; Dash, C.; Giardiello, F.M.; Glick, S.; Levin, T.R. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American cancer society, the US multi-society task force on colorectal cancer, and the American college of radiology. CA Cancer J. Clin. 2008, 58, 130–160.
14. Eaden, J.A.; Abrams, K.R.; Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001, 48, 526–535.
15. Canavan, C.; Abrams, K.R.; Mayberry, J. Meta-analysis: Colorectal and small bowel cancer risk in patients with crohn’s disease. Aliment. Pharmacol. Therap. 2006, 23, 1097–1104.
16. Johns, L.E.; Houlston, R.S. A systematic review and meta-analysis of familial colorectal cancer risk. Am. J. Gastroenterol. 2001, 96, 2992–3003.
17. Robertson, D.J. ABC of colorectal cancer. Gastroenterology 2012, 143, 868–869.
18. Martinez-Useros, J.; Garcia-Foncillas, J. Obesity and colorectal cancer: Molecular features of adipose tissue. J. Transl. Med. 2016, 14, 21.
19. Willett, W.C. Diet and cancer: An evolving picture. JAMA 2005, 293, 233–234.
20. Bastide, N.M.; Pierre, F.H.F.; Corpet, D.E. Heme iron from meat and risk of colorectal cancer: A meta-analysis and a review of the mechanisms involved. Cancer Prev. Res. 2011, 4, 177–184.
21. Santarelli, R.L.L.; Pierre, F.; Corpet, D.E. Processed meat and colorectal cancer: A review of epidemiologic and experimental evidence. Nutr. Cancer 2008, 60, 131–144.
22. Pöschl, G.; Seitz, H.K. Alcohol and cancer. Alcohol Alcoholism 2004, 39, 155–165.
23. Botteri, E.; Iodice, S.; Bagnardi, V.; Raimondi, S.; Lowenfels, A.B.; Maisonneuve, P. Smoking and colorectal cancer: A meta-analysis. JAMA 2008, 300, 2765–2778.
24. Cross, A.J.; Boca, S.; Freedman, N.D.; Caporaso, N.E.; Huang, W.Y.; Sinha, R.; Sampson, J.N.; Moore, S.C. Metabolites of tobacco smoking and colorectal cancer risk. Carcinogenesis 2014, 35, 1516–1522.
25. Liang, P.S.; Chen, T.Y.; Giovannucci, E. Cigarette smoking and colorectal cancer incidence and mortality: Systematic review and meta-analysis. Int. J. Cancer 2009, 124, 2406–2415.
26. Grady, W.M.; Carethers, J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135, 1079–1099.
27. Pino, M.S.; Chung, D.C. The chromosomal instability pathway in colon cancer. Gastroenterology 2010, 138, 2059–2072.
28. Boland, C.R.; Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 2010, 138, 2073–2087.
29. Lao, V.V.; Grady, W.M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 686–700.
30. Weisenberger, D.J.; Siegmund, K.D.; Campan, M.; Young, J.; Long, T.I.; Faasse, M.A.; Kang, G.H.; Widschwendter, M.; Weener, D.; Buchanan, D. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38, 787–793.
31. Willett, C.G.; Chang, D.T.; Czito, B.G.; Meyer, J.; Wo, J. Cancer genome atlas network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337.
32. Brocardo, M.; Henderson, B.R. APC shuttling to the membrane, nucleus and beyond. Trends Cell Boil. 2008, 18, 587–596.
33. Herzig, D.O.; Tsikitis, V.L. Molecular markers for colon diagnosis, prognosis and targeted therapy. J. Surg. Oncol. 2015, 111, 96–102.
34. Rennoll, S.; Yochum, G. Regulation of myc gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer. World J. Biol. Chem. 2015, 6, 290.
35. Toon, C.W.; Chou, A.; Clarkson, A.; DeSilva, K.; Houang, M.; Chan, J.C.Y.; Sioson, L.L.; Jankova, L.; Gill, A.J. Immunohistochemistry for myc predicts survival in colorectal cancer. PLoS ONE 2014, 9, e87456.
36. Chen, J.; Guo, F.; Shi, X.; Zhang, L.; Zhang, A.; Jin, H.; He, Y. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 2014, 14, 1.
37. Li, W.; Qiu, T.; Zhi, W.; Shi, S.; Zou, S.; Ling, Y.; Shan, L.; Ying, J.; Lu, N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 2015, 15, 1.
38. Ogino, S.; Nosho, K.; Kirkner, G.J.; Kawasaki, T.; Meyerhardt, J.A.; Loda, M.; Giovannucci, E.L.; Fuchs, C.S. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58, 90–96.
39. Goldstein, J.; Tran, B.; Ensor, J.; Gibbs, P.; Wong, H.L.; Wong, S.F.; Vilar, E.; Tie, J.; Broaddus, R.; Kopetz, S. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann. Oncol. 2014, 25, 1032–1038.
40. Kadowaki, S.; Kakuta, M.; Takahashi, S.; Takahashi, A.; Arai, Y.; Nishimura, Y.; Yatsuoka, T.; Ooki, A.; Yamaguchi, K.; Matsuo, K. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J. Gastroenterol. WJG 2015, 21, 1275.
41. Day, F.; Muranyi, A.; Singh, S.; Shanmugam, K.; Williams, D.; Byrne, D.; Pham, K.; Palmieri, M.; Tie, J.; Grogan, T. A mutant BRAF V600E-specific immunohistochemical assay: Correlation with molecular mutation status and clinical outcome in colorectal cancer. Target. Oncol. 2015, 10, 99–109.
42. Yaeger, R.; Cercek, A.; O’Reilly, E.M.; Reidy, D.L.; Kemeny, N.; Wolinsky, T.; Capanu, M.; Gollub, M.J.; Rosen, N.; Berger, M.F. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res. 2015, 21, 1313–1320.
43. Morkel, M.; Riemer, P.; Bläker, H.; Sers, C. Similar but different: Distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget 2015, 6, 20785.
44. Rosty, C.; Young, J.P.; Walsh, M.D.; Clendenning, M.; Sanderson, K.; Walters, R.J.; Parry, S.; Jenkins, M.A.; Win, A.K.; Southey, M.C. PIK3CA activating mutation in colorectal carcinoma: Associations with molecular features and survival. PLoS ONE 2013, 8, e65479.
45. Liao, X.; Morikawa, T.; Lochhead, P.; Imamura, Y.; Kuchiba, A.; Yamauchi, M.; Nosho, K.; Qian, Z.R.; Nishihara, R.; Meyerhardt, J.A. Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin. Cancer Res. 2012, 18, 2257–2268.
46. Atreya, C.E.; Sangale, Z.; Xu, N.; Matli, M.R.; Tikishvili, E.; Welbourn, W.; Stone, S.; Shokat, K.M.; Warren, R.S. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013, 2, 496–506.
47. Sarli, L.; Bottarelli, L.; Bader, G.; Iusco, D.; Pizzi, S.; Costi, R.; Bertolani, M.; Roncoroni, L.; Bordi, C. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis. Colon Rectum. 2004, 47, 1467–1482.
48. Popat, S.; Houlston, R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur. J. Cancer 2005, 41, 2060–2070.
49. Popat, S.; Zhao, D.; Chen, Z.; Pan, H.; Shao, Y.; Chandler, I.; Houlston, R.S. Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients. Anticancer Res. 2007, 27, 627–633.
50. Munro, A.J.; Lain, S.; Lane, D.P. P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br. J. Cancer 2005, 92, 434–444.
51. Rooney, P.; Boonsong, A.; McKay, J.; Marsh, S.; Stevenson, D.; Murray, G.; Curran, S.; Haites, N.; Cassidy, J.; McLeod, H. Colorectal cancer genomics: Evidence for multiple genotypes which influence survival. Br. J. Cancer 2001, 85, 1492.
52. Mattick, J.S.; Makunin, I.V. Non-coding RNA. Hum. Mol. Genet. 2006, 15, R17–R29.
53. Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J. mir-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 2008, 105, 13421–13426.
54. Lu, G.; Sun, Y.; An, S.; Xin, S.; Ren, X.; Zhang, D.; Wu, P.; Liao, W.; Ding, Y.; Liang, L. MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. Exp. Mol. Pathol. 2015, 99, 173–179.
55. Liu, M.; Chen, H. The role of microRNAs in colorectal cancer. J. Genet. Genom. 2010, 37, 347–358.
56. Migliore, L.; Migheli, F.; Spisni, R.; Coppedè, F. Genetics, cytogenetics, and epigenetics of colorectal cancer. BioMed Res. Int. 2011, 2011.
57. Asangani, I.; Rasheed, S.; Nikolova, D.; Leupold, J.; Colburn, N.; Post, S.; Allgayer, H. microRNA-21 (mir-21) post-transcriptionally downregulates tumor suppressor PDCD4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27, 2128–2136.
58. Tang, J.-T.; Wang, J.-L.; Du, W.; Hong, J.; Zhao, S.-L.; Wang, Y.-C.; Xiong, H.; Chen, H.-M.; Fang, J.-Y. MicroRNA 345, a methylation-sensitive microrna is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 2011, 32, 1207–1215.
59. Song, Y.; Xu, Y.; Wang, Z.; Chen, Y.; Yue, Z.; Gao, P.; Xing, C.; Xu, H. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int. J. Cancer 2012, 131, 1042–1051.
60. Han, H.B.; Gu, J.; Zuo, H.J.; Chen, Z.G.; Zhao, W.; Li, M.; Ji, D.B.; Lu, Y.Y.; Zhang, Z.Q. LET-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J. Pathol. 2012, 226, 544–555.
61. Wang, F.; Zhang, P.; Ma, Y.; Yang, J.; Moyer, M.P.; Shi, C.; Peng, J.; Qin, H. NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by LET-7a microRNA. Cancer Lett. 2012, 314, 223–231.
62. Liu, X.; Zhang, Z.; Sun, L.; Chai, N.; Tang, S.; Jin, J.; Hu, H.; Nie, Y.; Wang, X.; Wu, K. microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 2011, 32, 1798–1805.
63. Lv, H.; Zhang, Z.; Wang, Y.; Li, C.; Gong, W.; Wang, X. MicroRNA-92a promotes colorectal cancer cell growth and migration by inhibiting KLF4. Oncol. Res. Featur. Preclin. Clin. Cancer Ther. 2016, 23, 283–290.
64. Almeida, A.L.; Bernardes, M.V.; Feitosa, M.R.; Peria, F.M.; Tirapelli, D.P.; Rocha, J.J.; Feres, O. Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer. Acta Cir. Bras. 2016, 31, 13–18.
65. Vishnubalaji, R.; Hamam, R.; Yue, S.; Al-Obeed, O.; Kassem, M.; Liu, F.; Aldahmash, A.; Alajez, N. MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1. Oncotarget 2016.
66. Li, W.; Chang, J.; Wang, S.; Liu, X.; Peng, J.; Huang, D.; Sun, M.; Chen, Z.; Zhang, W.; Guo, W. miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mtor. Oncotarget 2015, 6, 24448–24462.
67. Park, Y.R.; Lee, S.T.; Kim, S.L.; Liu, Y.C.; Lee, M.R.; Shin, J.H.; Seo, S.Y.; Kim, S.H.; Kim, I.H.; Lee, S.O. microRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer. Int. J. Oncol. 2016, 48, 2135–2143.
68. Noguchi, T.; Toiyama, Y.; Kitajima, T.; Imaoka, H.; Hiro, J.; Saigusa, S.; Tanaka, K.; Inoue, Y.; Mohri, Y.; Toden, S. miRNA-503 promotes tumor progression and is associated with early recurrence and poor prognosis in human colorectal cancer. Oncology 2016, 90, 221–231.
69. Gao, H.; Bai, C.; Sun, Z. In microRNA-222 to enhance invasion and migration through MST3 in colorectal cancer and to predict for CRC patients progression. In Proceedings of the 2015 ASCO Annual Meeting Proceedings, Chicago, IL, USA, 29 May–2 June 2015; p. e22006.
70. Zhao, L.-D.; Zheng, W.-W.; Wang, G.-X.; Kang, X.-C.; Qin, L.; Ji, J.-J.; Hao, S. Epigenetic silencing of mir-181b contributes to tumorigenicity in colorectal cancer by targeting RASSF1A. Int. J. Oncol. 2016, 48, 1977–1984.
71. Qiu, Y.; Yu, H.; Shi, X.; Xu, K.; Tang, Q.; Liang, B.; Hu, S.; Bao, Y.; Xu, J.; Cai, J. microRNA-497 inhibits invasion and metastasis of colorectal cancer cells by targeting vascular endothelial growth factor-A. Cell Prolif. 2016, 49, 69–78.
72. Li, L.; Jia, F.; Bai, P.; Liang, Y.; Sun, R.; Yuan, F.; Zhang, L.; Gao, L. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of gastric cancer. Tumor Biol. 2016, 37, 299–303.
73. Zhang, F.; Luo, Y.; Shao, Z.; Xu, L.; Liu, X.; Niu, Y.; Shi, J.; Sun, X.; Liu, Y.; Ding, Y. microRNA-187, a downstream effector of TGF-β pathway, suppresses SMAD-mediated epithelial-mesenchymal transition in colorectal cancer. Cancer Lett. 2016, 373, 203–213.
74. Deng, W.; Wang, J.; Zhang, J.; Cai, J.; Bai, Z.; Zhang, Z. ORAI1, a direct target of microRNA-519, promotes progression of colorectal cancer via AKT/GSK3B signaling pathway. Digest. Dis. Sci. 2016, 61, 1–8.
75. Wan, Y.C.; Li, T.; Han, Y.D.; Zhang, H.Y.; Lin, H.; Zhang, B. microRNA-155 enhances the activation of WNT/β-catenin signaling in colorectal carcinoma by suppressing HMG-box transcription factor 1. Mol. Med. Rep. 2016.
76. Wang, L.; Jiang, C.; Li, D.; Ge, X.; Shi, Z.; Li, C.; Liu, X.; Yin, Y.; Zhen, L.; Liu, L.-Z. MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. Oncotarget 2015, 7, 2660–2671.
77. Zaharie, F.; Muresan, M.-S.; Petrushev, B.; Berce, C.; Gafencu, G.-A.; Selicean, S.; Jurj, A.; Cojocneanu-Petric, R.; Lisencu, C.-I.; Pop, L.-A. Exosome-carried microRNA-375 inhibits cell progression and dissemination via Bcl-2 blocking in colon cancer. J. Gastrointest. Liver Dis. 2015, 24, 435–443.
78. Wang, S.; Zeng, Y.; Zhou, J.M.; Nie, S.L.; Peng, Q.; Gong, J.; Huo, J.R. microRNA-1246 promotes growth and metastasis of colorectal cancer cells involving CCNG2 reduction. Mol. Med. Rep. 2016, 13, 273–280.
79. Xiao, R.; Li, C.; Chai, B. miRNA-144 suppresses proliferation and migration of colorectal cancer cells through GSPT1. Biomed. Pharmacother. 2015, 74, 138–144.
80. Zhang, J.; Bian, Z.; Zhou, J.; Song, M.; Liu, Z.; Feng, Y.; Zhe, L.; Zhang, B.; Yin, Y.; Huang, Z. microRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. Protein Cell 2015, 6, 680–688.
81. Chen, M.-B.; Yang, L.; Lu, P.-H.; Fu, X.-L.; Zhang, Y.; Zhu, Y.-Q.; Tian, Y. microRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells. Biochem. Biophys. Res. Commun. 2015, 463, 954–960.
82. Xu, T.; Jing, C.; Shi, Y.; Miao, R.; Peng, L.; Kong, S.; Ma, Y.; Li, L. microRNA-20a enhances the epithelial-to-mesenchymal transition of colorectal cancer cells by modulating matrix metalloproteinases. Exp. Ther. Med. 2015, 10, 683–688.
83. Bai, R.; Weng, C.; Dong, H.; Li, S.; Chen, G.; Xu, Z. microRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression. Int. J. Cancer 2015, 137, 2310–2322.
84. Morris, K.V.; Mattick, J.S. The rise of regulatory RNA. Nat. Rev. Genet. 2014, 15, 423.
85. Nie, L.; Wu, H.-J.; Hsu, J.-M.; Chang, S.-S.; LaBaff, A.M.; Li, C.-W.; Wang, Y.; Hsu, J.L.; Hung, M.-C. natures: Versatile master regulators of gene expression and crucial players in cancer. Am. J. Transl. Res. 2012, 4, 127–150.
86. Hamilton, M.J.; Young, M.D.; Sauer, S.; Martinez, E. The interplay of long non-coding RNAs and myc in cancer. AIMS Biophys. 2015, 2, 794–809.
87. Gibb, E.A.; Brown, C.J.; Lam, W.L. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 2011, 10, 1.
88. Tsang, W.P.; Ng, E.K.O.; Ng, S.S.M.; Jin, H.; Yu, J.; Sung, J.J.Y.; Kwok, T.T. Oncofetal H19-derived mir-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010, 31, 350–358.
89. Fellig, Y.; Ariel, I.; Ohana, P.; Schachter, P.; Sinelnikov, I.; Birman, T.; Ayesh, S.; Schneider, T.; de Groot, N.; Czerniak, A. H19 expression in hepatic metastases from a range of human carcinomas. J. Clin. Pathol. 2005, 58, 1064–1068.
90. Ohana, P.; Schachter, P.; Ayesh, B.; Mizrahi, A.; Birman, T.; Schneider, T.; Matouk, I.; Ayesh, S.; Kuppen, P.J.K.; de Groot, N. Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases. J. Gene Med. 2005, 7, 366–374.
91. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.-C.; Hung, T.; Argani, P.; Rinn, J.L. Long non-coding RNA hotair reprograms chromatin state to promote cancer metastasis. Nature 2010, 464, 1071–1076.
92. Schorderet, P.; Duboule, D. Structural and functional differences in the long non-coding RNA hotair in mouse and human. PLoS Genet 2011, 7, e1002071.
93. Xu, C.; Yang, M.H.; Tian, J.; Wang, X.Y.; Li, Z.G. Malat-1: A long non-coding RNA and its important 30 end functional motif in colorectal cancer metastasis. Int. J. Oncol. 2011, 39, 169.
94. Matouk, I.J.; Abbasi, I.; Hochberg, A.; Galun, E.; Dweik, H.; Akkawi, M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur. J. Gastroenterol. Hepatol. 2009, 21, 688–692.
95. Zhang, X.; Zhou, Y.; Mehta, K.R.; Danila, D.C.; Scolavino, S.; Johnson, S.R.; Klibanski, A. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J. Clin. Endocrinol. Metab. 2003, 88, 5119–5126.
96. Yang, F.; Xue, X.; Bi, J.; Zheng, L.; Zhi, K.; Gu, Y.; Fang, G. Long noncoding RNA CCAT1, which could be activated by c-myc, promotes the progression of gastric carcinoma. J. Cancer Res. Clin. Oncol. 2013, 139, 437–445.
97. Kim, T.; Cui, R.; Jeon, Y.-J.; Lee, J.-H.; Lee, J.H.; Sim, H.; Park, J.K.; Fadda, P.; Tili, E.; Nakanishi, H. Long–Range interaction and correlation between myc enhancer and oncogenic long noncoding RNA CARLO-5. Proc. Natl. Acad. Sci. USA 2014, 111, 4173–4178.
98. Ling, H.; Spizzo, R.; Atlasi, Y.; Nicoloso, M.; Shimizu, M.; Redis, R.S.; Nishida, N.; Gafà, R.; Song, J.; Guo, Z. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013, 23, 1446–1461.
99. Graham, L.D.; Pedersen, S.K.; Brown, G.S.; Ho, T.; Kassir, Z.; Moynihan, A.T.; Vizgoft, E.K.; Dunne, R.; Pimlott, L.; Young, G.P. Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Gene Cancer 2011, 2, 829–840.
100. Liu, Q.; Huang, J.; Zhou, N.; Zhang, Z.; Zhang, A.; Lu, Z.; Wu, F.; Mo, Y.-Y. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res. 2013, 41, 4976–4987.
101. Pibouin, L.; Villaudy, J.; Ferbus, D.; Muleris, M.; Prospéri, M.-T.; Remvikos, Y.; Goubin, G.R. Cloning of the mRNA of overexpression in colon carcinoma-1: A sequence overexpressed in a subset of colon carcinomas. Cancer Genet. Cytogenet. 2002, 133, 55–60.
102. Yang, F.; Zhang, H.; Mei, Y.; Wu, M. Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the Warburg effect. Mol. Cell 2014, 53, 88–100.
103. Nakano, S.; Murakami, K.; Meguro, M.; Soejima, H.; Higashimoto, K.; Urano, T.; Kugoh, H.; Mukai, T.; Ikeguchi, M.; Oshimura, M. Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KVDMR1 in colorectal cancers. Cancer Sci. 2006, 97, 1147–1154.
104. Poliseno, L.; Salmena, L.; Zhang, J.; Carver, B.; Haveman, W.J.; Pandolfi, P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465, 1033–1038.
105. Han, Y.J.; Ma, S.F.; Yourek, G.; Park, Y.-D.; Garcia, J.G.N. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J. 2011, 25, 2305–2312.
106. Panagopoulos, I.; Moller, E.; Collin, A.; Mertens, F. The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1 isoform 1. Oncol. Rep. 2008, 20, 1029–1033.
107. Wang, F.; Li, X.; Xie, X.; Zhao, L.; Chen, W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008, 582, 1919–1927.
108. Prensner, J.R.; Iyer, M.K.; Balbin, O.A.; Dhanasekaran, S.M.; Cao, Q.; Brenner, J.C.; Laxman, B.; Asangani, I.A.; Grasso, C.S.; Kominsky, H.D. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 2011, 29, 742–749.
109. Prensner, J.R.; Chen, W.; Iyer, M.K.; Cao, Q.; Ma, T.; Han, S.; Sahu, A.; Malik, R.; Wilder-Romans, K.; Navone, N. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014, 74, 1651–1660.
110. Ge, X.; Chen, Y.; Liao, X.; Liu, D.; Li, F.; Ruan, H.; Jia, W. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med. Oncol. 2013, 30, 1–6.
111. Chung, S.; Nakagawa, H.; Uemura, M.; Piao, L.; Ashikawa, K.; Hosono, N.; Takata, R.; Akamatsu, S.; Kawaguchi, T.; Morizono, T. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011, 102, 245–252.
112. Li, L.; Sun, R.; Liang, Y.; Pan, X.; Li, Z.; Bai, P.; Zeng, X.; Zhang, D.; Zhang, L.; Gao, L. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J. Exp. Clin. Cancer Res. 2013, 32, 1.
113. Yang, F.; Huo, X.S.; Yuan, S.X.; Zhang, L.; Zhou, W.P.; Wang, F.; Sun, S.H. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol. Cell 2013, 49, 1083–1096.
114. Qi, P.; Xu, M.D.; Ni, S.J.; Shen, X.H.; Wei, P.; Huang, D.; Tan, C.; Sheng, W.Q.; Zhou, X.Y.; Du, X. Down-regulation of NCRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Mol. Carcinog. 2015, 54, 742–750.
115. Tseng, Y.-Y.; Moriarity, B.S.; Gong, W.; Akiyama, R.; Tiwari, A.; Kawakami, H.; Ronning, P.; Reuland, B.; Guenther, K.; Beadnell, T.C. PVT1 dependence in cancer with myc copy-number increase. Nature 2014, 512, 82–86.
116. Takahashi, Y.; Sawada, G.; Kurashige, J.; Uchi, R.; Matsumura, T.; Ueo, H.; Takano, Y.; Eguchi, H.; Sudo, T.; Sugimachi, K. Amplification of PVT1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br. J. Cancer 2014, 110, 164–171.
117. Ahmed, F.E.; Ahmed, N.C.; Vos, P.W.; Bonnerup, C.; Atkins, J.N.; Casey, M.; Nuovo, G.J.; Naziri, W.; Wiley, J.E.; Mota, H. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genom. Proteom. 2013, 10, 93–113.
118. Yang, X.; Zhong, J.; Ji, Y.; Li, J.; Jian, Y.; Zhang, J.; Yang, W. The expression and clinical significance of microRNAs in colorectal cancer detecting. Tumor Biol. 2015, 36, 2675–2684.
119. Ursell, L.K.; Metcalf, J.L.; Parfrey, L.W.; Knight, R. Defining the human microbiome. Nutr. Rev. 2012, 70, S38–S44.
120. McNally, L.; Brown, S.P. Building the microbiome in health and disease: Niche construction and social conflict in bacteria. Phil. Trans. R. Soc. B 2015.
121. Scarpellini, E.; Ianiro, G.; Attili, F.; Bassanelli, C.; de Santis, A.; Gasbarrini, A. The human gut microbiota and virome: Potential therapeutic implications. Dig. Liver Dis. 2011, 47, 1007–1012.
122. Stearns, J.C.; Lynch, M.D.J.; Senadheera, D.B.; Tenenbaum, H.C.; Goldberg, M.B.; Cvitkovitch, D.G.; Croitoru, K.; Moreno-Hagelsieb, G.; Neufeld, J.D. Bacterial biogeography of the human digestive tract. Sci. Rep. 2011, 1.
123. Rajilic-Stojanovic, M.; Smidt, H.; de Vos, W.M. Diversity of the human gastrointestinal tract microbiota revisited. Environ. Microbial. 2007, 9, 2125–2136.
124. Matamoros, S.; Gras-Leguen, C.; Le Vacon, F.; Potel, G.; de La Cochetiere, M.-F. Development of intestinal microbiota in infants and its impact on health. Trends Microbial. 2013, 21, 167–173.
125. Yadav, D.; Ghosh, T.S.; Mande, S.S. Global investigation of composition and interaction networks in gut microbiomes of individuals belonging to diverse geographies and age-groups. Gut Pathog. 2016, 8, 1.
126. Yatsunenko, T.; Rey, F.E.; Manary, M.J.; Trehan, I.; Dominguez-Bello, M.G.; Contreras, M.; Magris, M.; Hidalgo, G.; Baldassano, R.N.; Anokhin, A.P. Human gut microbiome viewed across age and geography. Nature 2012, 486, 222–227.
127. Engen, P.A.; Green, S.J.; Voigt, R.M.; Forsyth, C.B.; Keshavarzian, A. The gastrointestinal microbiome: Alcohol effects on the composition of intestinal microbiota. Alcohol Res. Curr. Rev. 2015, 37, 223.
128. Xu, Z.; Knight, R. Dietary effects on human gut microbiome diversity. Br. J. Nutr. 2015, 113, S1–S5.
129. Ley, R.E.; Hamady, M.; Lozupone, C.; Turnbaugh, P.J.; Ramey, R.R.; Bircher, J.S.; Schlegel, M.L.; Tucker, T.A.; Schrenzel, M.D.; Knight, R. Evolution of mammals and their gut microbes. Science 2008, 320, 1647–1651.
130. Davenport, E.R.; Mizrahi-Man, O.; Michelini, K.; Barreiro, L.B.; Ober, C.; Gilad, Y. Seasonal variation in human gut microbiome composition. PLoS ONE 2014, 9, e90731.
131. Sankar, S.A.; Lagier, J.-C.; Pontarotti, P.; Raoult, D.; Fournier, P.-E. The human gut microbiome, a taxonomic conundrum. Syst. Appl. Microbial. 2015, 38, 276–286.
132. Cox, M.J.; Cookson, W.O.; Moffatt, M.F. Sequencing the human microbiome in health and disease. Hum. Mol. Genet. 2013, 22, 88–94.
133. Garza, D.R.; Dutilh, B.E. From cultured to uncultured genome sequences: Metagenomics and modeling microbial ecosystems. Cell. Mol. Life Sci. 2015, 72, 4287–4308.
134. Geuking, M.B.; Köller, Y.; Rupp, S.; McCoy, K.D. The interplay between the gut microbiota and the immune system. Gut Microb. 2014, 5, 411–418.
135. Chung, H.; Kasper, D.L. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr. Opin. Immunol. 2010, 22, 455–460.
136. Krishnan, S.; Alden, N.; Lee, K. Pathways and functions of gut microbiota metabolism impacting host physiology. Curr. Opin. Biotechnol. 2015, 36, 137–145.
137. Zhang, Y.-J.; Li, S.; Gan, R.-Y.; Zhou, T.; Xu, D.-P.; Li, H.-B. Impacts of gut bacteria on human health and diseases. Int. J. Mol. Sci. 2015, 16, 7493–7519.
138. Serino, M.; Blasco-Baque, V.; Nicolas, S.; Burcelin, R. Far from the eyes, close to the heart: Dysbiosis of gut microbiota and cardiovascular consequences. Curr. Cardiol. Rep. 2014, 16, 1–7.
139. Kim, Y.-G.; Udayanga, K.G.S.; Totsuka, N.; Weinberg, J.B.; Núñez, G.; Shibuya, A. Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE2. Cell Host Microb. 2014, 15, 95–102.
140. Iebba, V.; Totino, V.; Gagliardi, A.; Santangelo, F.; Cacciotti, F.; Trancassini, M.; Mancini, C.; Cicerone, C.; Corazziari, E.; Pantanella, F. Eubiosis and dysbiosis: The two sides of the microbiota. New Microbial. 2016, 39, 1–12.
141. Schippa, S.; Conte, M.P. Dysbiotic events in gut microbiota: Impact on human health. Nutrients 2014, 6, 5786–5805.
142. Nagao-Kitamoto, H.; Kitamoto, S.; Kuffa, P.; Kamada, N. Pathogenic role of the gut microbiota in gastrointestinal diseases. Intest. Res. 2016, 14, 127–138.
143. Peloquin, J.M.; Nguyen, D.D. The microbiota and inflammatory bowel disease: Insights from animal models. Anaerobe 2013, 24, 102–106.
144. Tomasello, G.; Tralongo, P.; Damiani, P.; Sinagra, E.; di Trapani, B.; Zeenny, M.N.; Hussein, I.H.; Jurjus, A.; Leone, A. Dismicrobism in inflammatory bowel disease and colorectal cancer: Changes in response of colocytes. World J. Gastroenterol. 2014, 20, 18121–18130.
145. Wu, N.; Yang, X.; Zhang, R.; Li, J.; Xiao, X.; Hu, Y.; Chen, Y.; Yang, F.; Lu, N.; Wang, Z. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb. Ecol. 2013, 66, 462–470.
146. Sheflin, A.M.; Whitney, A.K.; Weir, T.L. Cancer-promoting effects of microbial dysbiosis. Curr. Oncol. Rep. 2014, 16, 1–9.
147. Wang, T.; Cai, G.; Qiu, Y.; Fei, N.; Zhang, M.; Pang, X.; Jia, W.; Cai, S.; Zhao, L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012, 6, 320–329.
148. Zimmer, J.; Lange, B.; Frick, J.-S.; Sauer, H.; Zimmermann, K.; Schwiertz, A.; Rusch, K.; Klosterhalfen, S.; Enck, P. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur. J. Clin. Nutr. 2012, 66, 53–60.
149. David, L.A.; Maurice, C.F.; Carmody, R.N.; Gootenberg, D.B.; Button, J.E.; Wolfe, B.E.; Ling, A.V.; Devlin, A.S.; Varma, Y.; Fischbach, M.A. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505, 559–563.
150. Hung, R.J.; Ulrich, C.M.; Goode, E.L.; Brhane, Y.; Muir, K.; Chan, A.T.; Le Marchand, L.; Schildkraut, J.; Witte, J.S.; Eeles, R. Cross cancer genomic investigation of inflammation pathway for five common cancers: Lung, ovary, prostate, breast, and colorectal cancer. J. Natl. Cancer Inst. 2015, 107, 246.
151. Chai, E.Z.P.; Siveen, K.S.; Shanmugam, M.K.; Arfuso, F.; Sethi, G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem. J. 2015, 468, 1–15.
152. Ryan, B.M.; Wolff, R.K.; Valeri, N.; Khan, M.; Robinson, D.; Paone, A.; Bowman, E.D.; Lundgreen, A.; Caan, B.; Potter, J. An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiol. 2015, 38, 583–590.
153. Sobhani, I.; Amiot, A.; Le Baleur, Y.; Levy, M.; Auriault, M.-L.; van Nhieu, J.T.; Delchier, J.C. Microbial dysbiosis and colon carcinogenesis: Could colon cancer be considered a bacteria-related disease? Ther. Adv. Gastroenterol. 2013, 6, 215–229.
154. Schwabe, R.F.; Jobin, C. The microbiome and cancer. Nat. Rev. Cancer 2013, 13, 800–812.
155. Borges-Canha, M.; Portela-Cidade, J.P.; Dinis-Ribeiro, M.; Leite-Moreira, A.F.; Pimentel-Nunes, P. Role of colonic microbiota in colorectal carcinogenesis: A systematic review. Rev. Esp. Enferm. Dig. 2015, 107, 659–671.
156. Candela, M.; Turroni, S.; Biagi, E.; Carbonero, F.; Rampelli, S.; Fiorentini, C.; Brigidi, P. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J. Gastroenterol. 2014, 20, 908–922.
157. Zackular, J.P.; Baxter, N.T.; Iverson, K.D.; Sadler, W.D.; Petrosino, J.F.; Chen, G.Y.; Schloss, P.D. The gut microbiome modulates colon tumorigenesis. MBio 2013, 4, e00692-13.
158. Nosho, K.; Sukawa, Y.; Adachi, Y.; Ito, M.; Mitsuhashi, K.; Kurihara, H.; Kanno, S.; Yamamoto, I.; Ishigami, K.; Igarashi, H. Association of fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J. Gastroenterol. 2016, 22, 557–566.
159. Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microb. 2014, 14, 207–215.
160. Li, Y.-Y.; Ge, Q.-X.; Cao, J.; Zhou, Y.-J.; Du, Y.-L.; Shen, B.; Wan, Y.-J.Y.; Nie, Y.-Q. Association of fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J. Gastroenterol. 2016, 22, 3227.
161. McCoy, A.N.; Araujo-Perez, F.; Azcarate-Peril, A.; Yeh, J.J.; Sandler, R.S.; Keku, T.O. Fusobacterium is associated with colorectal adenomas. PLoS ONE 2013, 8, e53653.
162. Bashir, A.; Miskeen, A.Y.; Hazari, Y.M.; Asrafuzzaman, S.; Fazili, K.M. Fusobacterium nucleatum, inflammation, and immunity: The fire within human gut. Tumor Biol. 2016, 37, 2805–2810.
163. Sears, C.L.; Geis, A.L.; Housseau, F. Bacteroides fragilis subverts mucosal biology: From symbiont to colon carcinogenesis. J. Clin. Investing. 2014, 124, 4166–4172.
164. Boleij, A.; Hechenbleikner, E.M.; Goodwin, A.C.; Badani, R.; Stein, E.M.; Lazarev, M.G.; Ellis, B.; Carroll, K.C.; Albesiano, E.; Wick, E.C. The bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin. Infect. Dis. 2014.
165. Kohoutova, D.; Smajs, D.; Moravkova, P.; Cyrany, J.; Moravkova, M.; Forstlova, M.; Cihak, M.; Rejchrt, S.; Bures, J. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect. Dis. 2014, 14, 1.
166. Allen-Vercoe, E.; Jobin, C. Fusobacterium and enterobacteriaceae: Important players for CRC? Immunol. Lett. 2014, 162, 54–61.
167. Bonnet, M.; Buc, E.; Sauvanet, P.; Darcha, C.; Dubois, D.; Pereira, B.; Déchelotte, P.; Bonnet, R.; Pezet, D.; Darfeuille-Michaud, A. Colonization of the human gut by E. Coli and colorectal cancer risk. Clin. Cancer Res. 2014, 20, 859–867.
168. Moore, M.A.; Manan, A.A.; Chow, K.Y.; Cornain, S.F.; Devi, C.R.; Triningsih, F.X.; Laudico, A.; Mapua, C.A.; Mirasol-Lumague, M.R.; Noorwati, S. Cancer epidemiology and control in peninsular and island South-east Asia-past, present and future. Asian Pac. J. Cancer Prev. 2010, 11, 81–98.
169. Farazi, P.A. Cancer trends and risk factors in Cyprus. ecancermedicalscience 2014, 8.
170. Koifman, S.; Koifman, R.J. Environment and cancer in Brazil: An overview from a public health perspective. Rev. Mutat. Res. 2003, 544, 305–311.
171. Okreglicka, K. Health effects of changes in the structure of dietary macronutrients intake in western societies. Rocz. Panstw. Zakl. Hig. 2015, 66, 97–105.
172. Aykan, N.F. Red meat and colorectal cancer. Oncol. Rev. 2015, 9, 288.
173. Kim, E.; Coelho, D.; Blachier, F. Review of the association between meat consumption and risk of colorectal cancer. Nutr. Res. 2013, 33, 983–994.
174. Ou, J.; Carbonero, F.; Zoetendal, E.G.; DeLany, J.P.; Wang, M.; Newton, K.; Gaskins, H.R.; O’Keefe, S.J.D. Diet, microbiota, and microbial metabolites in colon cancer risk in rural africans and African americans. Am. J. Clin. Nutr. 2013, 98, 111–120.
175. Feng, Q.; Liang, S.; Jia, H.; Stadlmayr, A.; Tang, L.; Lan, Z.; Zhang, D.; Xia, H.; Xu, X.; Jie, Z. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat. Commun. 2015, 6.
176. O’Keefe, S.J.D.; Li, J.V.; Lahti, L.; Ou, J.; Carbonero, F.; Mohammed, K.; Posma, J.M.; Kinross, J.; Wahl, E.; Ruder, E. Fat, fibre and cancer risk in African americans and rural africans. Nat. Commun. 2015, 6.
177. Fung, K.Y.C.; Cosgrove, L.; Lockett, T.; Head, R.; Topping, D.L. A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. Br. J. Nutr. 2012, 108, 820–831.
178. Hofmanova, J.; Hyrslova Vaculova, A.; Kozubik, A. Regulation of the metabolism of polyunsaturated fatty acids and butyrate in colon cancer cells. Curr. Pharm. Biotechnol. 2013, 14, 274–288.
179. Donohoe, D.R.; Holley, D.; Collins, L.B.; Montgomery, S.A.; Whitmore, A.C.; Hillhouse, A.; Curry, K.P.; Renner, S.W.; Greenwalt, A.; Ryan, E.P. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota-and butyrate-dependent manner. Cancer Discov. 2014, 4, 1387–1397.
180. Diamandis, E.P. Cancer biomarkers: Can we turn recent failures into success? J. Natl. Cancer Inst. 2010, 102, 1462–1467.
181. Ludwig, J.A.; Weinstein, J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845–856.
182. Coghlin, C.; Murray, G.I. Biomarkers of colorectal cancer: Recent advances and future challenges. Proteom. Clin. Appl. 2015, 9, 64–71.
183. Bacher, J.W.; Flanagan, L.A.; Smalley, R.L.; Nassif, N.A.; Burgart, L.J.; Halberg, R.B.; Megid, W.M.A.; Thibodeau, S.N. Development of a fluorescent multiplex assay for detection of MSI-high tumors. Dis. Mark. 2004, 20, 237–250.
184. Geiersbach, K.B.; Samowitz, W.S. Microsatellite instability and colorectal cancer. Arch. Pathol. Lab. Med. 2011, 135, 1269–1277.
185. Iacopetta, B.; Watanabe, T. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006, 55, 1671–1672.
186. De Roock, W.; Claes, B.; Bernasconi, D.; de Schutter, J.; Biesmans, B.; Fountzilas, G.; Kalogeras, K.T.; Kotoula, V.; Papamichael, D.; Laurent-Puig, P. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010, 11, 753–762.
187. Aprile, G.; Macerelli, M.; De Maglio, G.; Pizzolitto, S.; Fasola, G. The relevance of BRAF and extended ras mutational analyses for metastatic colorectal cancer patients. OA Mol. Oncol. 2013, 1, 7.
188. Kislitsin, D.; Lerner, A.; Rennert, G.; Lev, Z. KRAS mutations in sporadic colorectal tumors in Israel: Unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes. Dig. Dis. Sci. 2002, 47, 1073–1079.
189. Fransén, K.; Klintenas, M.; Osterstrom, A.; Dimberg, J.; Monstein, H.-J.; Soderkvist, P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25, 527–533.
190. Wong, R.; Cunningham, D. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J. Clin. Oncol. 2008, 26, 5668–5670.
191. Sartore-Bianchi, A.; Martini, M.; Molinari, F.; Veronese, S.; Nichelatti, M.; Artale, S.; di Nicolantonio, F.; Saletti, P.; de Dosso, S.; Mazzucchelli, L. PIK3CA mutations in colorectal cancer are associated with clinical resistance to egfr-targeted monoclonal antibodies. Cancer Res. 2009, 69, 1851–1857.
192. Wheeler, J.M.D.; Loukola, A.; Aaltonen, L.A.; Mortensen, N.J.M.; Bodmer, W.F. The role of hypermethylation of thehmlh1 promoter region in hnpcc versus MSI+ sporadic colorectal cancers. J. Med. Genet. 2000, 37, 588–592.
193. Gonzalez-Pons, M.; Cruz-Correa, M. Colorectal cancer biomarkers: Where are we now? BioMed Res. Int. 2015, 2015, 1–14.
194. Umetani, N.; Kim, J.; Hiramatsu, S.; Reber, H.A.; Hines, O.J.; Bilchik, A.J.; Hoon, D.S.B. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for alu repeats. Clin. Chem. 2006, 52, 1062–1069.
195. Barrier, A.; Boelle, P.-Y.; Roser, F.O.; Gregg, J.; Tse, C.; Brault, D.; Lacaine, F.O.; Houry, S.; Huguier, M.; Franc, B. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J. Clin. Oncol. 2006, 24, 4685–4691.
196. Wang, Y.; Jatkoe, T.; Zhang, Y.; Mutch, M.G.; Talantov, D.; Jiang, J.; McLeod, H.L.; Atkins, D. Gene expression profiles and molecular markers to predict recurrence of dukes’ B colon cancer. J. Clin. Oncol. 2004, 22, 1564–1571.
197. Takai, T.; Kanaoka, S.; Yoshida, K.-I.; Hamaya, Y.; Ikuma, M.; Miura, N.; Sugimura, H.; Kajimura, M.; Hishida, A. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol. Biomark. Prev. 2009, 18, 1888–1893.
198. Link, A.; Balaguer, F.; Shen, Y.; Nagasaka, T.; Lozano, J.J.; Boland, C.R.; Goel, A. Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomark. Prev. 2010, 19, 1766–1774.
199. Khambata-Ford, S.; Garrett, C.R.; Meropol, N.J.; Basik, M.; Harbison, C.T.; Wu, S.; Wong, T.W.; Huang, X.; Takimoto, C.H.; Godwin, A.K. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25, 3230–3237.
200. Jacobs, B.; de Roock, W.; Piessevaux, H.; van Oirbeek, R.; Biesmans, B.; de Schutter, J.; Fieuws, S.; Vandesompele, J.; Peeters, M.; van Laethem, J.-L. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 2009, 27, 5068–5074.
201. Baker, J.B.; Dutta, D.; Watson, D.; Maddala, T.; Munneke, B.M.; Shak, S.; Rowinsky, E.K.; Xu, L.A.; Harbison, C.T.; Clark, E.A. Tumour gene expression predicts response to cetuximab in patients with kras wild-type metastatic colorectal cancer. Br. J. Cancer 2011, 104, 488–495.
202. Von Roon, A.C.; Karamountzos, L.; Purkayastha, S.; Reese, G.E.; Darzi, A.W.; Teare, J.P.; Paraskeva, P.; Tekkis, P.P. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am. J. Gastroenterol. 2007, 102, 803–813.
203. Xing, P.X.; Young, G.P.; Ho, D.; Sinatra, M.A.; Hoj, P.B.; McKenzie, I.F.C. A new approach to fecal occult blood testing based on the detection of haptoglobin. Cancer 1996, 78, 48–56.
204. Quaye, I.K. Haptoglobin, inflammation and disease. Trans. R. Soc. Trop. Med. Hyg. 2008, 102, 735–742.
205. Hundt, S.; Haug, U.; Brenner, H. Blood markers for early detection of colorectal cancer: A systematic review. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1935–1953.
206. Holten-Andersen, M.N.; Christensen, I.J.; Nielsen, H.; Stephens, R.W.; Jensen, V.; Nielsen, O.H.; Sørensen, S.; Overgaard, J.; Lilja, H.; Harris, A. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin. Cancer Res. 2002, 8, 156–164.
207. Sastre, J.; Maestro, M.L.; Puente, J.; Veganzones, S.; Alfonso, R.; Rafael, S.; Garcia-Saenz, J.A.; Vidaurreta, M.; Martin, M.; Arroyo, M. Circulating tumor cells in colorectal cancer: Correlation with clinical and pathological variables. Ann. Oncol. 2008, 19, 935–938.
208. Cohen, S.J.; Punt, C.J.A.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.A.; Mitchell, E.; Miller, M.C. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009, 20, 1223–1229.
209. Uen, Y.-H.; Lu, C.-Y.; Tsai, H.-L.; Yu, F.-J.; Huang, M.-Y.; Cheng, T.-L.; Lin, S.-R.; Wang, J.-Y. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I–III colorectal cancer after curative resection. Ann. Surg. Oncol. 2008, 15, 2120–2128.
210. Bertucci, F.; Salas, S.; Eysteries, S.; Nasser, V.; Finetti, P.; Ginestier, C.; Charafe-Jauffret, E.; Loriod, B.; Bachelart, L.C.; Montfort, J.M. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004, 23, 1377–1391.
211. Marshall, K.W.; Mohr, S.; Khettabi, F.E.; Nossova, N.; Chao, S.; Bao, W.; Ma, J.; Li, X.-J.; Liew, C.-C. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int. J. Cancer 2010, 126, 1177–1186.
212. Yip, K.-T.; Das, P.K.; Suria, D.; Lim, C.-R.; Ng, G.-H.; Liew, C.-C. A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J. Exp. Clin. Cancer Res. 2010, 29, 1.
213. Yothers, G.; O’Connell, M.J.; Lee, M.; Lopatin, M.; Clark-Langone, K.M.; Millward, C.; Paik, S.; Sharif, S.; Shak, S.; Wolmark, N. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J. Clin. Oncol. 2013, 31, 4512–4519.
214. Srivastava, G.; Renfro, L.A.; Behrens, R.J.; Lopatin, M.; Chao, C.; Soori, G.S.; Dakhil, S.R.; Mowat, R.B.; Kuebler, J.P.; Kim, G. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist 2014, 19, 492–497.
215. Salazar, R.; Roepman, P.; Capella, G.; Moreno, V.; Simon, I.; Dreezen, C.; Lopez-Doriga, A.; Santos, C.; Marijnen, C.; Westerga, J. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 2010.
216. Maak, M.; Simon, I.; Nitsche, U.; Roepman, P.; Snel, M.; Glas, A.M.; Schuster, T.; Keller, G.; Zeestraten, E.; Goossens, I.S. Independent validation of a prognostic genomic signature (coloprint) for patients with stage II colon cancer. Ann. Surg. 2013, 257, 1053–1058.
217. Kennedy, R.D.; Bylesjo, M.; Kerr, P.; Davison, T.; Black, J.M.; Kay, E.W.; Holt, R.J.; Proutski, V.; Ahdesmaki, M.; Farztdinov, V. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J. Clin. Oncol. 2011, 29, 4620–4626.
218. Sveen, A.; Nesbakken, A.; Agesen, T.H.; Guren, M.G.; Tveit, K.M.; Skotheim, R.I.; Lothe, R.A. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: Is godot finally arriving? Clin. Cancer Res. 2013, 19, 6669–6677.
219. Lenehan, P.F.; Boardman, L.A.; Riegert-Johnson, D.; de Petris, G.; Fry, D.W.; Ohrnberger, J.; Heyman, E.R.; Gerard, B.; Almal, A.A.; Worzel, W.P. Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma. Cancer 2012, 118, 5234–5244.
220. Black, E.R.; Falzon, L.; Aronson, N. Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer; Report No.: 12 (13)-EHC143-EF; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2012.
221. Carlson, M.R. Previstage (TM) GCC colorectal cancer staging test: A new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol. Diagn. Ther. 2009, 13, 11.
222. Van Cutsem, E.; Nordlinger, B.; Cervantes, A.; Group, E.G.W. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann. Oncol. 2010, 21, 93–97.
223. Van Cutsem, E.; Cervantes, A.; Nordlinger, B.; Arnold, D. Metastatic colorectal cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 5, 1–9.
224. Venook, A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005, 10, 250–261.
225. Prehn, R.T. The inhibition of tumor growth by tumor mass. Cancer Res. 1991, 51, 2–4.
226. Brown, L.M.; Malkinson, A.M.; Rannels, D.E.; Rannels, S.R. Compensatory lung growth after partial pneumonectomy enhances lung tumorigenesis induced by 3-methylcholanthrene. Cancer Res. 1999, 59, 5089–5092.
227. Smith, B.H.; Gazda, L.S.; Conn, B.L.; Jain, K.; Asina, S.; Levine, D.M.; Parker, T.S.; Laramore, M.A.; Martis, P.C.; Vinerean, H.V. Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth. Cancer Res. 2011, 71, 725–735.
228. Asina, S.; Jain, K.; Rubin, A.L.; Smith, B.; Stenzel, K. Cancer-Cell Proliferation-Suppressing Material Produced by Cancer Cells Restricted by Entrapment. Google Patents U.S. 6303151 B1, 16 October 2001.
229. Ocean, A.J.; Parikh, T.; Berman, N.; Escalon, J.; Shah, M.A.; Andrada, Z.; Akahoho, E.; Pogoda, J.M.; Stoms, G.B.; Escobia, V.B. Phase I/II trial of intraperitoneal implantation of agarose-agarose macrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA) in patients (PTS) with advanced colorectal cancer (CRC). In Proceedings of the 2013 ASCO Annual Meeting, Chicago, IL, USA, 31 May–4 June 2013; p. e14517.
230. Janakiram, N.B.; Rao, C.V. The role of inflammation in colon cancer. Adv. Exp. Med. Biol. 2014, 816, 25–52.
231. Suh, O.; Mettlin, C.; Petrelli, N.J. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993, 72, 1171–1177.
232. Rigau, J.; Piqué, J.M.; Rubio, E.; Planas, R.N.; Tarrech, J.M.; Bordas, J.M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med. 1991, 115, 952–954.
233. Suh, N.; Reddy, B.S.; DeCastro, A.; Paul, S.; Lee, H.J.; Smolarek, A.K.; So, J.Y.; Simi, B.; Wang, C.X.; Janakiram, N.B. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats. Cancer Prev. Res. 2011, 4, 1895–1902.
234. Ungprasert, P.; Cheungpasitporn, W.; Crowson, C.S.; Matteson, E.L. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur. J. Intern. Med. 2015, 26, 285–291.
235. Gupta, R.A.; DuBois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1, 11–21.
236. Jüni, P.; Nartey, L.; Reichenbach, S.; Sterchi, R.; Dieppe, P.A.; Egger, M. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004, 364, 2021–2029.
237. Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N.M.; Stenson, W.F. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The class study: A randomized controlled trial. JAMA 2000, 284, 1247–1255.
238. Solomon, S.D.; McMurray, J.J.V.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352, 1071–1080.
239. McDonald, B.F.; Quinn, A.M.; Devers, T.; Cullen, A.; Coulter, I.S.; Marison, I.W.; Loughran, S.T. In-vitro characterisation of a novel celecoxib microbead formulation for the treatment and prevention of colorectal cancer. J. Pharm. Pharmacol. 2015, 67, 685–695.
240. Lev-Ari, S.; Strier, L.; Kazanov, D.; Madar-Shapiro, L.; Dvory-Sobol, H.; Pinchuk, I.; Marian, B.; Lichtenberg, D.; Arber, N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 2005, 11, 6738–6744.
241. Kahouli, I.; Tomaro-Duchesneau, C.; Prakash, S. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J. Med. Microbial. 2013, 62, 1107–1123.
242. Zhong, L.; Zhang, X.; Covasa, M. Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J. Gastroenterol. 2014, 20, 7878–7886.
243. Chong, E.S.L. A potential role of probiotics in colorectal cancer prevention: Review of possible mechanisms of action. World J. Microbiol. Biotechnol. 2014, 30, 351–374.
244. Pala, V.; Sieri, S.; Berrino, F.; Vineis, P.; Sacerdote, C.; Palli, D.; Masala, G.; Panico, S.; Mattiello, A.; Tumino, R. Yogurt consumption and risk of colorectal cancer in the italian european prospective investigation into cancer and nutrition cohort. Int. J. Cancer 2011, 129, 2712–2719.
245. Chen, C.-C.; Lin, W.-C.; Kong, M.-S.; Shi, H.N.; Walker, W.A.; Lin, C.-Y.; Huang, C.-T.; Lin, Y.-C.; Jung, S.-M.; Lin, T.-Y. Oral inoculation of probiotics lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. Br. J. Nutr. 2012, 107, 1623–1634.
246. Choi, S.S.; Kim, Y.; Han, K.S.; You, S.; Oh, S.; Kim, S.H. Effects of lactobacillus strains on cancer cell proliferation and oxidative stress in vitro. Lett. Appl. Microbial. 2006, 42, 452–458.
247. Sah, B.N.P.; Vasiljevic, T.; McKechnie, S.; Donkor, O.N. Effect of probiotics on antioxidant and antimutagenic activities of crude peptide extract from yogurt. Food Chem. 2014, 156, 264–270.
248. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Boil. 2007, 39, 44–48.
249. Circu, M.L.; Aw, T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Rad. Biol. Med. 2010, 48, 749–762.
250. Sena, L.A.; Chandel, N.S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 2012, 48, 158–167.
251. Guimarães, R.; Barros, L.; Carvalho, A.M.; Ferreira, I.C. Studies on chemical constituents and bioactivity of rosa micrantha: An alternative antioxidants source for food, pharmaceutical, or cosmetic applications. J. Agric. Food Chem. 2010, 58, 6277–6284.
252. Ferreira, I.C.; Barros, L.; Abreu, R. Antioxidants in wild mushrooms. Curr. Med. Chem. 2009, 16, 1543–1560.
253. Carocho, M.; Barros, L.; Barreira, J.C.; Calhelha, R.C.; Sokovic, M.; Fernández-Ruiz, V.; Buelga, C.S.; Morales, P.; Ferreira, I.C. Basil as functional and preserving ingredient in “serra da estrela” cheese. Food Chem. 2016, 207, 51–59.
254. Montero, P.; Calvo, M.; Gómez-Guillén, M.; Gómez-Estaca, J. Microcapsules containing astaxanthin from shrimp waste as potential food coloring and functional ingredient: Characterization, stability, and bioaccessibility. LWT Food Sci. Technol. 2016, 70, 229–236.
255. Hansen, C. Grape Seed Extract: Procyanidolic Oligomers (PCO); Healing Wisdom Publications: New York, NY, USA, 1995.
256. Macheix, J.-J.; Fleuriet, A. Fruit Phenolics; CRC Press Inc.: Boca Raton, FL, USA, 1990.
257. Velioglu, Y.; Mazza, G.; Gao, L.; Oomah, B. Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products. J. Agric. Food chem. 1998, 46, 4113–4117.
258. Shi, J.; Nawaz, H.; Pohorly, J.; Mittal, G.; Kakuda, Y.; Jiang, Y. Extraction of polyphenolics from plant material for functional foods—Engineering and technology. Food Rev. Int. 2005, 21, 139–166.
259. Wenzel, U.; Kuntz, S.; Brendel, M.D.; Daniel, H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res. 2000, 60, 3823–3831.
260. Pandey, K.B.; Rizvi, S.I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev. 2009, 2, 270–278.
261. Shahidi, F.; Ambigaipalan, P. Phenolics and polyphenolics in foods, beverages and spices: Antioxidant activity and health effects—A review. J. Funct. Foods 2015, 18, 820–897.
262. Jiménez, S.; Gascón, S.; Luquín, A.; Laguna, M.; Ancin-Azpilicueta, C.; Rodríguez-Yoldi, M.J. Rosa canina extracts have antiproliferative and antioxidant effects on caco-2 human colon cancer. PLoS ONE 2016, 11, e0159136.
263. Liu, J.; Shi, J.-Z.; Yu, L.-M.; Goyer, R.A.; Waalkes, M.P. Mercury in traditional medicines: Is cinnabar toxicologically similar to common mercurials? Exp. Boil. Med. 2008, 233, 810–817.
264. Miller, A.C.; Rashid, R.M.; Falzon, L.; Elamin, E.M.; Zehtabchi, S. Silver sulfadiazine for the treatment of partial-thickness burns and venous stasis ulcers. J. Am. Acad. Dermatol. 2012, 66, 159–165.
265. Zhao, W.; Liu, L.; Wang, Y.; Mao, T.; Li, J. Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp. Ther. Med. 2016, 11, 183–190.
266. Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014, 740, 364–378.
267. Muhammad, N.; Guo, Z. Metal-based anticancer chemotherapeutic agents. Curr. Opin. Chem. Boil. 2014, 19, 144–153.
268. Komeda, S.; Casini, A. Next-generation anticancer metallodrugs. Curr. Top. Med. Chem. 2012, 12, 219–235.
269. Garbutcheon-Singh, K.B.; Grant, M.P.; Harper, B.W.; Krause-Heuer, A.M.; Manohar, M.; Orkey, N.; Aldrich-Wright, J.R. Transition metal based anticancer drugs. Curr. Top. Med. Chem. 2011, 11, 521–542.
270. Frezza, M.; Hindo, S.; Chen, D.; Davenport, A.; Schmitt, S.; Tomco, D.; Dou, Q.P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des. 2010, 16, 1813–1825.
271. Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39, 8113–8127.
272. WoYniak, K.; Blasiak, J. Recognition and repair of DNA-cisplatin adducts. Acta Biochim. Pol. 2002, 49, 583–596.
273. Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. Third row transition metals for the treatment of cancer. Philos. Trans. R. Soc. Lond. A Math. Phys. Eng. Sci. 2015.
274. Karasawa, T.; Steyger, P.S. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol. Lett. 2015, 237, 219–227.
275. Peres, L.A.B.; de Cunha, A.D. Acute nephrotoxicity of cisplatin: Molecular mechanisms. J. Bras. Nefrol. 2013, 35, 332–340.
276. Gonçalves, M.S.; Silveira, A.F.; Teixeira, A.R.; Hyppolito, M.A. Mechanisms of cisplatin ototoxicity: Theoretical review. J. Laryngol. Otol. 2013, 127, 536–541.
277. Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265–7279.
278. Amable, L. Cisplatin resistance and opportunities for precision medicine. Pharmacol. Res. 2016, 106, 27–36.
279. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307–320.
280. Hoff, P.M.; Saad, E.D.; Costa, F.; Coutinho, A.K.; Caponero, R.; Prolla, G.; Gansl, R.C. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin. Colorectal Cancer 2012, 11, 93–100.
281. De Gramont, A.D.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18, 2938–2947.
282. Ciombor, K.K.; Wu, C.; Goldberg, R.M. Recent therapeutic advances in the treatment of colorectal cancer. Ann. Rev. Med. 2015, 66, 83–95.
283. Hu, C.; Li, X.; Wang, W.; Zhang, R.; Deng, L. Metal-N-heterocyclic carbene complexes as anti-tumor agents. Curr. Med. Chem. 2014, 21, 1220–1230.
284. Lammer, A.D.; Cook, M.E.; Sessler, J.L. Synthesis and anti-cancer activities of a water soluble gold (III) porphyrin. J. Porphyr. Phthalocyanines 2015, 19, 398–403.
285. Lum, C.T.; Wong, A.S.-T.; Lin, M.C.M.; Che, C.-M.; Sun, R.W.-Y. A gold (III) porphyrin complex as an anti-cancer candidate to inhibit growth of cancer-stem cells. Chem. Commun. 2013, 49, 4364–4366.
286. Schmitt, S.M.; Frezza, M.; Dou, Q.P. New applications of old metal-binding drugs in the treatment of human cancer. Front. Biosci. 2012, 4, 375.
287. Chaffman, M.; Brogden, R.N.; Heel, R.C.; Speight, T.M.; Avery, G.S. Auranofin. Drugs 1984, 27, 378–424.
288. Roder, C.; Thomson, M.J. Auranofin: Repurposing an old drug for a golden new age. Drugs R&D 2015, 15, 13–20.
289. Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Rad. Biol. Med. 2007, 42, 872–881.
290. Ortego, L.; Cardoso, F.; Martins, S.; Fillat, M.F.; Laguna, A.; Meireles, M.; Villacampa, M.D.; Gimeno, M.C. Strong inhibition of thioredoxin reductase by highly cytotoxic gold (I) complexes. DNA binding studies. J. Inorg. Biochem. 2014, 130, 32–37.
291. Garcia, A.; Machado, R.C.; Grazul, R.M.; Lopes, M.T.P.; Correa, C.C.; dos Santos, H.F.; de Almeida, M.V.; Silva, H. Novel antitumor adamantane-azole gold (I) complexes as potential inhibitors of thioredoxin reductase. J. Biol. Inorg. Chem. 2016, 21, 275–292.
292. Galassi, R.; Burini, A.; Ricci, S.; Pellei, M.; Rigobello, M.P.; Citta, A.; Dolmella, A.; Gandin, V.; Marzano, C. Synthesis and characterization of azolate gold (I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents. Dalton Trans. 2012, 41, 5307–5318.
293. Tsuji, P.A.; Carlson, B.A.; Yoo, M.-H.; Naranjo-Suarez, S.; Xu, X.-M.; He, Y.; Asaki, E.; Seifried, H.E.; Reinhold, W.C.; Davis, C.D. The 15 kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways. PLoS ONE 2015, 10, e0124487.
294. Mahmood, D.F.D.; Abderrazak, A.; El Hadri, K.; Simmet, T.; Rouis, M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid. Redox signal. 2013, 19, 1266–1303.
295. Konstantinopoulos, P.A.; Papavassiliou, A.G. The potential of proteasome inhibition in the treatment of colon cancer. Expert Opin. Investig. Drugs 2006, 15, 1067–1075.
296. Liu, N.; Huang, H.; Dou, Q.P.; Liu, J. Inhibition of 19s proteasome-associated deubiquitinases by metal-containing compounds. Oncoscience 2015, 2, 457.
297. Buac, D.; Schmitt, S.; Ventro, G.; Rani Kona, F.; Dou, Q.P. Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells. Mini Rev. Med. Chem. 2012, 12, 1193–1201.
298. Zhang, X.; Frezza, M.; Milacic, V.; Ronconi, L.; Fan, Y.; Bi, C.; Fregona, D.; Dou, Q.P. Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and-independent processes. J. Cell. Biochem. 2010, 109, 162–172.
299. García-Moreno, E.; Gascón, S.; Rodriguez-Yoldi, M.J.; Cerrada, E.; Laguna, M. S-propargylthiopyridine phosphane derivatives as anticancer agents: Characterization and antitumor activity. Organometallics 2013, 32, 3710–3720.
300. García-Moreno, E.; Gascón, S.; Atrián-Blasco, E.; Rodriguez-Yoldi, M.J.; Cerrada, E.; Laguna, M. Gold (I) complexes with alkylated PTA (1, 3, 5-triaza-7-phosphaadamantane) phosphanes as anticancer metallodrugs. Eur. J. Med. Chem. 2014, 79, 164–172.
301. Garcia-Moreno, E.; Gascón, S.; Garcia de Jalon, J.; Romanos, E.; Jesus Rodriguez-Yoldi, M.; Cerrada, E.; Laguna, M. In vivo anticancer activity, toxicology and histopathological studies of the thiolate gold (I) complex [Au (Spyrimidine) (PTA-CH2Ph)]Br. Anti-Cancer Agents Med. Chem. 2015, 15, 773–782.
302. García-Moreno, E.; Tomás, A.; Atrián-Blasco, E.; Gascón, S.; Romanos, E.; Rodriguez-Yoldi, M.J.; Cerrada, E.; Laguna, M. In vitro and in vivo evaluation of organometallic gold (I) derivatives as anticancer agents. Dalton Trans. 2016, 45, 2462–2475.
303. Atrián-Blasco, E.; Gascón, S.; Rodríguez-Yoldi, M.J.; Laguna, M.; Cerrada, E. Synthesis of gold (I) derivatives bearing alkylated 1, 3, 5-triaza-7-phosphaadamantane as selective anticancer metallodrugs. Eur. J. Inorg. Chem. 2016, 2791–2803.